Abstract Aims/hypothesis: Proinsulin C-peptide is involved in several biological activities. However, the role of C-peptide in vascular smooth muscle cells is unclear. We therefore investigated its effects, in vascular smooth muscle cells in high-glucose conditions. Methods: Rat aortic smooth muscle cells were cultured with 5.5 or 20 mmol/l glucose with or without C-peptide (1 to 100 nmol/l) for 3 weeks. Proliferation activities, the protein expression of platelet-derived growth factor (PDGF)-beta receptor, the phosphorylation of p42/p44 mitogen-activated protein (MAP) kinases, and glucose uptake were measured.
Introduction
C-peptide is a 31-amino-acid peptide that is cleaved from the processing of proinsulin to insulin. For decades, Cpeptide was considered to have no biological effects. But recently, many investigators have revealed that the administration of C-peptide reduced the glomerular filtration rate and restored nerve functions and blood flow in diabetic animals or type 1 diabetic patients [1] [2] [3] [4] [5] [6] [7] [8] . Moreover, the administration of C-peptide elicits a substantial increase in whole-body glucose turnover in diabetic rats [9, 10] .
In the vasculature, the effects of C-peptide are controversial. C-peptide induces vasodilation via the increased production of nitric oxide from vascular endothelial cells [11] [12] [13] [14] . On the other hand, C-peptide accumulates in the vessel wall in early atherogenesis in diabetic animals and patients and stimulates chemotaxis of monocytes/CD4 + cells, subsequently migrating into the vessel wall [15, 16] . To date the effect of C-peptide on vascular smooth muscle cells (VSMCs) has not been reported. Since the migration and proliferation of VSMCs are the essential pathological changes in diabetic macroangiopathy, it is vital to assess the effects of C-peptide on VSMCs.
One of the mechanisms by which the growth of VSMCs is increased in atherosclerotic lesions is elevated sensitivity to platelet-derived growth factor (PDGF). Walker and coworkers reported that VSMCs in atherosclerotic lesions showed increasing expression of the PDGF-beta receptor and produced PDGF-like molecules [17] . We, and others, have reported that the growth rate of cultured VSMCs under high-glucose conditions was elevated via increased protein expression of PDGF-beta receptor [18] [19] [20] [21] . In addition, it has been demonstrated that PDGF stimulates cell growth and migration via the p42/p44 mitogen-activated protein (MAP) kinase pathway in VSMCs [22] .
The aim of this study is to reveal the role of C-peptide in VSMCs. Using a culture system, we investigated whether the administration of C-peptide affects proliferation, expression of the PDGF-beta receptor, phosphorylation of the p42/p44 MAP kinases, and glucose transport activities in VSMCs under high-glucose conditions.
Materials and methods
Materials Reagents were obtained from the following sources: rat aortic smooth muscle cells (SMCs) (A10 cells) from the American Type Culture Collection (Manassas, VA, USA); DMEM, penicillin-streptomycin, and FBS from Gibco (Grand Island, NY, USA). Human C-peptide was kindly provided by Eli Lilly (Indianapolis, IN, USA). Scrambled human C-peptide (the same amino acid residues as in C-peptide, but assembled in random order) was from Sigma Genosys (Cambridge, UK). Whatman GF/C filters were from Whatman International (Maidstone, UK). Rabbit anti-human PDGF-beta receptor antibody, and rabbit antihuman p42/p44 MAP kinase antibody came from Upstate Biotechnology (Lake Placid, NY, USA). Rabbit antiphospho-human p42/p44 MAP kinase was supplied by Cell Signaling Technology (Beverly, MA, USA). Chemiluminescence detection kits and [ Cell culture Rat aortic SMCs (A10 cells) were grown in DMEM containing 5.5 mmol/l glucose and 10% FBS, pH 7.4, at 37°C in a humidified 5% CO 2 /95% air atmosphere. Third or fourth passage cells from the purchase were grown for 3 weeks in DMEM containing 5.5 or 20 mmol/l glucose with or without C-peptide or scrambled C-peptide (1 to 100 nmol/l), and were used in subsequent experiments. For experiments with acute stimulation with C-peptide, cells were serum-starved overnight and stimulated with C-peptide or scrambled C-peptide for 10 min.
Assay of proliferation activities in SMCs Cells were plated on six-well plates at a density of 1×10 4 cells/cm 2 and grown in each experimental medium as described above. The proliferation activity in SMCs was assessed by determining [ 3 H]-thymidine incorporation into DNA as previously described [23] .
Immunoblot analyses After incubation with each experimental medium for the indicated periods, cells were washed three times with ice-cold PBS and lysed in a buffer containing 50 mmol/l Tris-HCl, pH 7.4, 1% Triton X-100, 0.25% sodium deoxycholate, 150 mmol/l NaCl, 1 mmol/l EGTA, 1 mmol/l phenylmethylsulphonyl fluoride, 1 μg/ml aprotinin, 1 μg/ml leupeptin, 1 mmol/l Na 3 VO 4 , and 1 mmol/l NaF at 4°C. Samples containing the same amount of protein were electrophoresed on SDS-PAGE and transferred to a nitrocellulose membrane. The membrane was incubated overnight at 4°C with the first antibody, followed by incubation with an HRP-conjugated anti-rabbit polyclonal IgG antibody. The proteins were visualised using ECL chemiluminescence detection kits. Protein expression was quantified by densitometry.
Assay of glucose transport activities in SMCs After 3 weeks of culture in normal or high-glucose conditions with or without C-peptide, unlabelled and labelled 2-deoxyglucose (0.1 mmol/l, 0.74 kBq/well) were added to the cells in the PBS buffer (138 mmol/l NaCl, 8.1 mmol/l Na 2 HPO 4 , 2.6 mmol/l KCl, 0.5 mmol/l MgSO 4 , 0.1 mmol/l CaCl 2 , 1.5 mmol/l KH 2 PO 4, at pH 7.4) with 1% BSA. The cells were then incubated for 6 min at 37°C. The reaction was stopped by washing the cells three times with ice-cold PBS. The cells were solubilised in 1 ml of solution. Radioactivity was quantified using a liquid scintillation counter (LSC-5100; Aloka, Tokyo, Japan).
Statistical analysis Results were expressed as means±SEM. Statistical analyses were made by one-way ANOVAwith the Bonferroni correction for multiple comparisons. A p value of p<0.05 was considered statistically significant. 
Results
Effects of C-peptide on proliferation activities of SMCs As shown in Fig. 1 , the proliferation activities of SMCs under high-glucose conditions increased by 3.38±0.62-fold compared with SMCs in normal glucose conditions (p<0.05). The 3-week administration of C-peptide suppressed the glucose-induced increase of thymidine incorporation in a dose-dependent manner (C-peptide, 1 nmol/l: 33.9±11.2%, 10 nmol/l: 48.1±8.7% (p<0.05), 100 nmol/l: 56.9±4.4%, p<0.01; reduction in comparison with high-glucose control). In contrast, C-peptide had no effects on the proliferation activities of SMCs under the normal glucose conditions. Scrambled C-peptide had no effects either under the normal or the high-glucose conditions.
Effects of C-peptide on protein expression of PDGF-beta receptor in SMCs Protein expression of PDGF-beta receptor increased by 3.35±0.60-fold under the high-glucose conditions (p<0.05) (Fig. 2) . The 3-week administration of Cpeptide suppressed the glucose-induced increase of protein expression of PDGF-beta receptor in a dose-dependent Effects of C-peptide on activation of p42/p44 MAP kinases in SMCs After 3 weeks, the activities of p42 and p44 MAP kinases in SMCs cultured in high-glucose conditions were elevated compared with those in SMCs in the normal glucose conditions (increase: 2.56±0.46 and 2.71±0.35-fold, respectively, p<0.05, Fig. 3 ). The administration of Cpeptide (10 and 100 nmol/l ) for 3 weeks reduced the increase in phosphorylation of p42/p44 MAP kinases that had been induced by high glucose (p<0.05). However, Cpeptide did not affect phosphorylation of p42/p44 MAP kinase under the normal glucose conditions. Scrambled Cpeptide had no effects, either in the normal, or in the highglucose conditions.
Effects of C-peptide on glucose transport activities of SMCs Glucose uptake was decreased in SMCs cultured in high-glucose conditions (decrease: 40.1±6.9%, compared with SMCs in normal glucose conditions, p<0.05) (Fig. 4) . Treatment with C-peptide reversed, in a dose-dependent manner, the decrease in glucose uptake that had been induced by high glucose, with 100 nmol/l of C-peptide ameliorating glucose uptake by 71.6±17.4% in the highglucose conditions (p<0.05). However, C-peptide did not affect glucose uptake in the normal glucose conditions. Scrambled C-peptide had no effects, either in normal or in high-glucose conditions.
Effects of acute exposure to C-peptide on p42/p44 MAP kinases To examine the acute effects of C-peptide in SMCs, cells were incubated with 0.3-100 nmol/l of Cpeptide for 10 min. As shown in Fig. 5 , acute exposure to C-peptide or scrambled C-peptide did not affect phosphorylation of p42/p44 MAP kinases in SMCs.
Discussion
The results presented in this study indicate that C-peptide inhibits the following effects that are induced by high glucose in SMCs: hyperproliferation, increased protein expression of PDGF-beta receptor, and increased phosphorylation of p44/p42 MAP kinases. These results suggest that C-peptide suppresses the growth of SMCs that is induced by high glucose via inhibition of the PDGFbeta receptor/p44/42 MAP kinases pathway. Our results also showed that C-peptide reversed the impairment of glucose utilisation in SMCs under high-glucose conditions. C-peptide is cleaved from proinsulin and co-secreted with insulin in response to glucose stimulation. Insulin has been reported to accelerate SMC growth and promote atherosclerosis via the activation of p44/42 MAP kinases [24] [25] [26] [27] . The proliferation of SMCs is one of the major pathological changes in atherosclerotic lesions occurring in the diabetic state [28] . Increased expression of PDGF-beta receptor has been demonstrated in atherosclerotic lesions and SMCs cultured under high-glucose conditions [19] . Because insulin increases the expression of PDGF-beta receptor and stimulates the growth of SMCs, its unbeneficial effects on atherosclerosis have been controversial in the treatment of diabetic patients. Here, our results indicate that C-peptide has an opposite effect to that of insulin on the growth of SMCs. We have shown that C-peptide inhibited the high-glucose-induced growth of SMCs in a dose-dependent manner. Moreover, C-peptide also suppressed protein expression of PDGF-beta receptor and phosphorylation of p42/p44 MAP kinases, doing this dosedependently at concentrations of 10 to 100 nmol/l. It is interesting that insulin and C-peptide, which are secreted at the same time from the pancreatic beta cell, have opposite effects on the growth of SMCs. C-peptide could play an important role in preventing SMC proliferation. Moreover, because the inhibitory effects of C-peptide on SMC growth occur in a dose-dependent manner, our results suggest that the additional administration of C-peptide to diabetic patients may inhibit the development of diabetic macroangiopathy. Our results show that the chronic administration of human C-peptide produced significant effects in rat SMCs, the maximum effect being observed at 100 nmol/l of Cpeptide. On the other hand, Henriksson and colleagues [29] showed that specific binding of C-peptide to the cell membranes of human skin fibroblast gave full saturation at approximately 0.9 nmol/l, and another team reported that lower concentrations of rat II C-peptide, such as 0.3-3.0 nmol C-peptide, had a maximum effect on MAP kinase in rat skeletal myoblasts [30] . Since we used human Cpeptide in rat SMCs, one of the probable reasons why the higher concentrations of C-peptide were required to obtain the significant effects is the difference in the species of Cpeptide, which is consistent with a previous report demonstrating that a 1,000-fold increase in the concentrations of human C-peptide, compared with rat II C-peptide, was needed to achieve maximum effects on rat tissues [8] .
The acute exposure with human C-peptide at concentrations of 1 to 100 nmol/l did not activate p42/p44 MAP kinases in rat SMCs in our study. Since our preliminary study had shown that human C-peptide phosphorylated MAP kinase at concentrations of 0.3 to 100 nmol/l in human SMCs (data not shown), the discrepancy in the effects of Cpeptide between rat and human SMCs is probably the result of the difference in the species. However, there is a substantial homology between rat and human C-peptide [1] . Moreover, the chronic effects of C-peptide in SMCs under normal or high-glucose conditions in this study cannot be compared with the acute effects of C-peptide. Further studies are required to address these questions.
In our study, 1 nmol/l of C-peptide tended to inhibit SMC growth without suppressing PDGF-beta receptor expression or MAP kinase activities. Although one of the major pathways stimulating SMC growth is the PDGF/MAP kinase pathway, other mechanisms may also be affected by C-peptide. Further studies are underway in our laboratory.
Zierath and co-workers [31] reported that C-peptide stimulates the rate of glucose transport in a dose-dependent manner in isolated human skeletal muscle strips in vitro. In clinical studies, C-peptide increased whole-body glucose turnover [9, 10] . Here, we have demonstrated that Cpeptide increased glucose utilisation in a dose-dependent manner in SMCs under high-glucose conditions. This is consistent with previous reports with other types of tissues. However, it remains unknown what role this effect of Cpeptide on glucose metabolism plays in the proliferation of SMCs.
In summary, chronic administration of C-peptide ameliorated high-glucose-induced hyperproliferation via suppression of a PDGF-beta receptor/MAP kinase pathway and high-glucose-induced suppression of glucose uptake in SMCs. This suggests that C-peptide may suppress atherosclerosis in diabetic patients. Concentrations of C-peptide differ in type 2 diabetic patients. In patients with insulin resistance, C-peptide is increased, whereas it is decreased in patients with insulin deficiency. Although the precise mechanisms of C-peptide's effects are still unclear, our results suggest C-peptide could be useful in the treatment of atherosclerosis, not only in C-peptide-deficient type 1 diabetic patients, but also in some type 2 diabetic patients who have a relative deficiency of C-peptide.
